Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.

Neuroendocrinology is a discipline which originated about 50 years ago as a branch of Endocrinology and that is now strictly linked to neuroscience.

Volumes 181 and 182 of Progress in Brain Researchprovide a rapid view of the major points presently discussed at biological and clinical levels.

The chapters have been written by top scientists who are directly involved in basic or clinical research and who use the most sophisticated biotechnological techniques.

The volumes cover of the role of genetics in many endocrine-related events, like neuroendocrinological diseases and endocrine depenedent cancers (prostate, breast, etc, ). Interesting information is also provided on possibile treatments of neurodegenerative brain diseases (e.g., Alzheimer and similar syndromes).

The best researchers in the field provide their conclusions in the context of the latest experimental results

Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered

Of great value for researchers and experts, but also for students as a background reference"

Neuroendocrinology is a discipline which originated about 50 years ago as a branch of Endocrinology and that is now strictly linked to neuroscience.

Volumes 181 and 182 of Progress in Brain Researchprovide a rapid view of the major points presently discussed at biological and clinical levels.

The chapters have been written by top scientists who are directly involved in basic or clinical research and who use the most sophisticated biotechnological techniques.

The volumes cover of the role of genetics in many endocrine-related events, like neuroendocrinological diseases and endocrine depenedent cancers (prostate, breast, etc, ). Interesting information is also provided on possibile treatments of neurodegenerative brain diseases (e.g., Alzheimer and similar syndromes).

The best researchers in the field provide their conclusions in the context of the latest experimental results

Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered

Of great value for researchers and experts, but also for students as a background reference"

Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.